He said that with shrinking debt, the life-sciences company plans to uplist to a national exchange before the end of the year.
“Although we are a QB company on the OTC Marketplace, we run the company as if we were NASDAQ or NYSE-Amex listed. This is important, since we have expectations of moving up to a national stock exchange before the end of this year,” Schumacher told the “Stock Day Podcast” on the Uptick Network Radio.
The Harvard Medical School-trained serial entrepreneur said Pressure BioSciences has been “working diligently” to meet the requirements necessary to uplist to a national exchange.
On June 12, the company converted an additional US$7.24mln of debt into equity, bringing the total amount of debt that it has converted into equity over the past four weeks to more than US$13.6mln.
As a result of its move to pay down its debt and the bolster its revenue, the company’s finances are on more solid ground.
READ: Pressure BioSciences invigorates its balance sheet, converts additional US$7.24mln of debt into equity
Pressure BioSciences was founded in 1978 and is based in South Easton, Massachusetts. It develops pressure cycling technology (PCT) solutions and is a leader in high pressure-based technologies, platforms, and services.
Hundreds of labs utilize the company's pressure-based systems to extract proteins carefully from cells and separate lipids, DNA, RNA and smart molecules from biological samples.
“We’re changing a paradigm that’s existed in labs for maybe 50 years,” said Schumacher.
Many other extraction methods used by over 500,000 researchers worldwide involve breaking cells open in more volatile ways that can actually damage the biomolecule contents or put researchers at risk.
PBI’s unique technology is more like squeezing a sponge, and the number of squeezes and level of pressure necessary for each unique cell type can be programmed into a computer that is part of their instrument. Individualizing profiles for human, plant, animal, and other normal or cancer cell types can promote consistency in research.
“High pressure has not really been utilized that much in the lab up to now, mainly because until we came along, there was really no way of safely getting high pressure into the lab,” Schumacher told the “Stock Day Podcast.”
“We use pressures up to six times the pressure you would feel if you were standing at the bottom of Mariana’s Trench, with six miles of ocean on top of you. Now that is pressure,” he said.
Schumacher went on to tell the podcast that their pressure chambers can “safely reach levels up to 100,000 PSI, a staggering high” in the industry.
In 2017, the company pulled in revenue of $US2.24mln by selling 300 pressure cycling technology (PCT) machines to more than 175 customers.
However, 2018 is already shaping up as a banner year. The company’s total revenue for the opening three months of 2018 rose 11% to US$610,774, up from US$551,357 in the year-ago quarter, thanks to booming sales of the company’s lab instruments which utilize pressure to control bio-molecular interactions.
The Stock Day Podcast host Everett Jolly noted that with a market cap of about US$4.2mln and shares selling at just under US$3 it was a “great time for investors” to get a look at Pressure BioSciences.
“It’s an extremely undervalued company. It’s one of those undiscovered gems for which investors are always looking. The company has done very well over the past 18-24 months, and we expect they will continue to do well, yet their stock price is actually down about 75% over that time. At some point, we believe they will be discovered,” said Jolly.
“Until then, in our opinion, the stock price is not even close to a true reflection of the value of this company.”
Shares of the company were up 2.56% to US$4 in morning trading.